Teva opts out of Rexahn's tumor drug candidate

Over the past few years, Rexahn ($RNN) has regularly cited its development pact with Teva ($TEVA) for a preclinical tumor drug dubbed RX-3117 as a cause for hope in the little biotech's future. Today, Rexahn issued word that Teva had nipped that one in the bud, choosing not to exercise its option for the therapy as it neared the clinic. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.